FDA approves Vibativ for hospitalized patients with bacterial pneumonia

The U.S. Food and Drug Administration today expanded the approved use of the antibiotic Vibativ (telavancin) to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by Staphylococcus aureus. Vibativ should be used for the treatment of HABP/VABP only when alternative treatments are not suitable.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm358209.htm

Source: Food and Drug Administration - June 21, 2013 Category: American Health Source Type: news